Endo Pharmaceuticals Holdings Inc. $345,000,000 1.75% Convertible Senior Subordinated Notes Due 2015 Purchase AgreementEndo Pharmaceuticals Holdings Inc • April 15th, 2008 • Pharmaceutical preparations • New York
Endo Pharmaceuticals Holdings Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to issue and sell to you (the “Initial Purchasers”), for whom Deutsche Bank Securities Inc. (the “Representative”) is acting as representative, $345,000,000 aggregate principal amount of its 1.75% Convertible Senior Subordinated Notes due 2015 (the “Firm Securities”). The Company also proposes to grant to the Initial Purchasers an option to purchase up to $34,500,000 aggregate principal amount of such Senior Subordinated Notes to cover over-allotments, if any (the “Option Securities” and, together with the Firm Securities, the “Securities”). The Securities are convertible into shares of Common Stock, par value $0.01 per share (the “Common Stock”), of the Company, subject to certain conditions described in the Final Memorandum (as defined below). The Securities are to be issued under an indenture (the “Indenture”), to be dated as of the Closing Date, between the Company and T
